Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TREAT Act Wants Accelerated Approval Change, But Uses Existing Language

Executive Summary

Anticipated legislation from Sen. Kay Hagan would copy federal regulations outlining accelerated approval to Food, Drug and Cosmetic Act, also encourage use of more broadly effective processes for expedited reviews.

Advertisement

Related Content

FDA Accelerated Approval For Rare Diseases Again Under Congressional Pressure
Temple: FDASIA Directs FDA To Learn To Use Existing Authority
Drug Shortages: Generic Industry’s Self Regulation Proposal Questioned At House Hearing
Accelerated Approval Expansion Proposals Pending, But One Needs An Overhaul
PDUFA V: Can FDA Fight Off Mission Creep This Cycle?
FDA Conflict Of Interest Policy May Be Biggest Conflict Of PDUFA Reauthorization
BIO Wants Expanded Accelerated Approval In PDUFA Instead Of Progressive Approval
Accelerated Approval Could Expand As Alternative To Progressive Approval
User Fee Negotiations: Should Consumer Stakeholders Sit At Table With Industry, FDA?
BIO’s "Big Ideas" For FDA Reform Are Too Big For PDUFA

Topics

Advertisement
UsernamePublicRestriction

Register

PS054224

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel